The gut microbiome and nonalcoholic fatty liver disease
AASLD LiverLearning®, Brian Nadeau, 203819
Primary sclerosing cholangitis: Unique aspects of disease in children
AASLD LiverLearning®, Jillian M. Cotter, 203820
ABO‐incompatible liver transplantation: Is it a viable option with modern innovation?
AASLD LiverLearning®, Abbas Rana, 203821
Pathological patterns of biliary disease
AASLD LiverLearning®, Jason Lewis, 203822
Nonobese nonalcoholic fatty liver disease
AASLD LiverLearning®, sammy saab, 203823
Drug‐drug interactions in hepatitis C virus treatment: Do they really matter?
AASLD LiverLearning®, Paul Kwo, 203824
Controversies in hepatitis C therapy: Reactivation of hepatitis B virus
AASLD LiverLearning®, Michael Fried, 203451
HCV treatment in patients with decompensated liver disease
AASLD LiverLearning®, Elizabeth C. Verna, 203452
Substance use disorders before and after liver transplantation
AASLD LiverLearning®, Jason L. Eccleston, 203453
Nonsurgical options for localized hepatocellular carcinoma
AASLD LiverLearning®, Johnathan Ha, 203454
Normothermic machine perfusion of the liver
AASLD LiverLearning®, CORRESPONDENCE Garrett R. Roll, 203455
Small‐for‐size syndrome in LT
AASLD LiverLearning®, Taizo Hibi, 203456
Clinical  Hepatology Debrief
AASLD LiverLearning®, Kris Kowdley, 202145
Clinical  Hepatology Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202146
NAFLD Debrief
AASLD LiverLearning®, Kymberly Watt, 202143
NAFLD Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202144
Hepatitis Debrief
AASLD LiverLearning®, Paul Kwo, 202141
Hepatitis Debrief: Introduction
AASLD LiverLearning®, Michael Fried, 202142
Leon Schiff SOA: Acute on Chronic Liver Failure: Introduction
AASLD LiverLearning®, Guadalupe Garcia-Tsao, 202140
Mayo Spheroid Reservoir Bio-Artificial Liver Improves Survival and Promotes Liver Regeneration in Post Hepatectomy ALF Pigs
AASLD LiverLearning®, Harvey Chen, 201444
Chemical and Toxicology Analysis of Ayurvedic and Herbal Drugs Causing Severe Liver Injury
AASLD LiverLearning®, Cyriac Philips, 201445
Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure
AASLD LiverLearning®, YI LI, 201446
Development of a new inhibitory antibody for prevention of HCV infection
AASLD LiverLearning®, Ken Okai, 201447
Human stem cell-derived Encapsulated Mature Liver Tissue as an effective, consistent, and durable in vitro tool for drug testing and development
AASLD LiverLearning®, Massimiliano Paganelli, 201448
The Frequency of Herbal and Dietary Supplement Mislabeling: Experience of the Drug Induced Liver Injury Network
AASLD LiverLearning®, Victor Navarro, 201449
HCV Patient Populations With Challenging Treatment Decisions
AASLD LiverLearning®, Paul Pockros, 202138
Ultrasound-based Elastography for NAFLD
AASLD LiverLearning®, Laurent Castera, 202132
New HCV Therapies in 2017 and Their Impact on Treatment Strategies
AASLD LiverLearning®, Paul Kwo, 202137
Global Perspectives on HCV Eradication
AASLD LiverLearning®, Philippa Easterbrook, 202136
Magnetic Resonance Elastography for NAFLD
AASLD LiverLearning®, Rohit Loomba, 202131
From the AASLD-IDSA Guidance Committee: How We Make Our Recommendations, What Important Gaps Remain in the Care of HCV Patients?
AASLD LiverLearning®, Susanna Naggie, 202135
HCV 2017 Treatment Symposium: Program Chair
AASLD LiverLearning®, Andrew Muir, 202133
Assessing Severity of Portal Hypertension and Prognosis
AASLD LiverLearning®, Massimo Pinzani, 202130
How Accurate is the Diagnosis of Cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 202129
AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease: Program Chair
AASLD LiverLearning®, Jayant Talwalkar, 202127
Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease: Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 202124
NAFLD in Children: A Global Perspective
AASLD LiverLearning®, Miriam Vos, 202123
African Content Perspective – AFASLD
AASLD LiverLearning®, Hisham El Khayat, 202122
South American Perspective – ALEH
AASLD LiverLearning®, Marco Arrese, 202121
Asia-Pacific Perspective – APASL
AASLD LiverLearning®, Barjesh Sharma, 202120
Hans Popper Basic Science SOA: Gut Microbiota and Liver
AASLD LiverLearning®, Bernd Schnabl, 202125
European Perspective – EASL
AASLD LiverLearning®, Frank Tacke, 202119
Hans Popper Basic Science SOA: Gut Microbiota and Liver: Introduction
AASLD LiverLearning®, Gavin Arteel, 202126
Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease: Program Chair
AASLD LiverLearning®, Zobair Younossi, 202116
Should Patients with HCV Early Stage & HCC Receive Concomitant Therapy?
AASLD LiverLearning®, Laura Kulik, 202110
New Treatment Algorithm for Management of Autoimmune Hepatitis
AASLD LiverLearning®, John Vierling, 202115
Do DAA Therapies for HCV Increase HCC Recurrence: No?
AASLD LiverLearning®, Amit Singal, 202109
New Strategies for Diagnosis and Surveillance of Cholangiocarcinoma in PSC
AASLD LiverLearning®, Christoph Schramm, 202114
Do DAA Therapies for HCV increase HCC Recurrence: Yes?
AASLD LiverLearning®, Maria Reig, 202108
Advances in the Management of PBC
AASLD LiverLearning®, Christopher Bowlus, 202113
Do DAA Therapies for HCV Increase HCC Recurrence Following Liver Transplantation: Yes?
AASLD LiverLearning®, Michael Leise, 202105
HCV SVR and HCC Incidence: DAA Era
AASLD LiverLearning®, Nathalie GANNE CARRIE, 202104
Hepatobiliary Neoplasia SIG: HCV Therapy and HCC: Program Chair
AASLD LiverLearning®, Gregory Gores, 202100
Hepatobiliary Neoplasia SIG: HCV Therapy and HCC: Session I Moderator
AASLD LiverLearning®, Augusto Villanueva, 202102
HCV SVR and HCC Incidence: Interferon Era
AASLD LiverLearning®, Hashem B. El-Serag, 202103
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science
AASLD LiverLearning®, Mark Avigan, 202098
Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science: Introduction
AASLD LiverLearning®, Robert Fontana, 202099
ClinIcal Educator/Mentor Award (DCEMA)
AASLD LiverLearning®, Session Speakers, 202097
Metagenomic analysis shows a shift in taxonomic and functional composition of the gut microbiota in NASH patients
AASLD LiverLearning®, Jérôme Boursier, 195709
A National Survey of Physicians Regarding Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH): The Disease and Clinical Trial Awareness Program for NASH
AASLD LiverLearning®, Zobair Younossi, 195775
Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
AASLD LiverLearning®, Stephen Harrison, 195660
The Impact Of Obeticholic Acid (OCA) On Atherogenic Lipoproteins In Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Arun Sanyal, 195688
Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a model of non-alcoholic fatty liver disease (NAFLD).
AASLD LiverLearning®, Nadine Gehrke, 195524
Lipoprotein sub-fractions show increased cardiovascular disease risk in pediatric non-alcoholic steatohepatitis compared to non-alcoholic fatty liver
AASLD LiverLearning®, Juna Konomi, 195634
Evaluating the Response to Placebo in Randomized Controlled Trials of Nonalcoholic Steatohepatitis: A systematic review and meta-analysis
AASLD LiverLearning®, Ma Ai Thanda Han, 195675
NGM282 Ameliorates Hepatic Lipotoxicity as Measured by Lipidomics and Gene Expression in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 195548
Cross talk between Sirtuins and TGF-β signaling - new models for non alcoholic steatohepatitis and progression to HCC
AASLD LiverLearning®, Lopa Mishra, 195531
Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Naotaka Shimozato, 195540
The secretin (SCT)/secretin receptor (SR) axis alters microRNA levels carried in extracellular vesicles that are responsible for cell-cell communication between cholangiocytes
AASLD LiverLearning®, Keisaku Sato, 195286
Role of endothelial dysfunction in microRNA-34a knockout mice with cholestatic liver injury
AASLD LiverLearning®, Tianhao Zhou, 195287
YAP/β-catenin cross-talk promotes a pro-inflammatory phenotype in Fibrocystin-defective cholangiocytes
AASLD LiverLearning®, Luca Fabris, 195288
An essential role of macrophages in cholangiocyte regeneration in a model of specific cholangiocyte injury
AASLD LiverLearning®, Adrien Guillot, 195289
Heritable variation of redox homeostasis is a potential risk factor for biliary disease
AASLD LiverLearning®, Xiao Zhao, 195290
Targeting YAP in Cholangiocarcinoma (CCA) induces cell senescence while blocking cell proliferation
AASLD LiverLearning®, Massimiliano Cadamuro, 195292
Cholangiocytes from Patients with Primary Biliary Cholangitis Display The Warburg Effect with Increased Mitochondria, Oxygen Consumption and Glycolytic Activity
AASLD LiverLearning®, Filip Wysokinski, 195293
Inhibition of HDAC6 and autophagy reverts ciliary loss and decreases proliferation rates in cholangiocarcinoma cells
AASLD LiverLearning®, Estanislao Peixoto, 195294
Changing Expression Profiles of lncRNAs, mRNAs, circRNAs and miRNAs in Biliary Epithelial Cells after Bile Acid (TDCA) Stimulation
AASLD LiverLearning®, Eric Gershwin, 195295
Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC).
AASLD LiverLearning®, Tianhao Zhou, 195296
The microRNA-200c Is a Critical Novel Regulator of Cholestatic Liver Fibrosis
AASLD LiverLearning®, Yongfeng Song, 195298
Pharmacological inhibition of ASBT-mediated intestinal reuptake of bile acids promotes hepatic expansion of regulatory T cells in murine sclerosing cholangitis
AASLD LiverLearning®, Ramesh Kudira, 195299
CCL4-induced cirrhosis and aging differentially modulate spingosine-1 phosphate receptors and sphingosine kinases in the brain
AASLD LiverLearning®, Yunzhou Li, 195300
The Apelin/Apelin receptor axis promotes biliary proliferation and liver fibrosis during biliary cholestasis
AASLD LiverLearning®, Marinda Scrushy, 195301
NTCP inhibition has hepatoprotective effects in cholestasis by lowering bile salt load on hepatocytes and increasing the biliary phospholipid vs bile salt ratio
AASLD LiverLearning®, Reinout Roscam Abbing, 195302
Cenicriviroc, a cytokine receptor antagonist, potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models
AASLD LiverLearning®, Dongke Yu, 195303
The thyromimetic GC-1 improves biliary injury but exacerbates hepatocyte injury in a mouse model of cholestasis
AASLD LiverLearning®, Kari Nejak-Bowen, 195304
Coffee mediated effects on transcriptional regulation of human UDP-glucuronosyltransferases (UGTs) during obstructive cholestasis (BDL) in a humanized transgenic UGT1A mouse model
AASLD LiverLearning®, Steffen Landerer, 195306
Treatment of cholestatic bile duct ligated (BDL) mice with a menin-MLL inhibitor reduces biliary damage and liver fibrosis
AASLD LiverLearning®, Laurent Ehrlich, 195307
Obesity exacerbates the neurological impairments associated to hepatic encephalopathy in chronic liver disease
AASLD LiverLearning®, Rafael Ochoa-Sanchez, 195308
Protective effect of phosphatidylcholine against lysophosphatidylcholine-induced cytotoxicity in cholangiocytes: a potential therapeutic target in cholangiocarcinoma
AASLD LiverLearning®, Akiko Sugiyama, 195309
Exposure to gulf war illness-related chemicals increases susceptibility to cholestatic liver injury by enhancing CD11b+ macrophage/monocyte infiltration into the liver
AASLD LiverLearning®, Jessica Kain, 195310
Cholecystectomy increases secondary bile acids in the liver and results in liver injury in male but not female mice
AASLD LiverLearning®, Dongke Yu, 195311
NK cells in the ascites of patients with advanced liver cirrhosis are phenotypically distinct from blood and liver NK cells and may be involved in antibacterial defense
AASLD LiverLearning®, Philipp Lutz, 195312
Rising Trend and Poor Waitlist Outcomes in Young Adult Liver Transplant Registrants with Alcoholic Liver Disease
AASLD LiverLearning®, George Cholankeril, 195313
Performance of the calprotectin assay in ascitic fluid using the Quantum Blue® Reader for the diagnosis of spontaneous bacterial peritonitis in cirrhotic patients (The CADRISLA Study)
AASLD LiverLearning®, Delphine Weil Verhoeven, 195314
A novel TIPS-controlled expansion stent for the treatment of severe portal hypertension. A single center experience.
AASLD LiverLearning®, Ioannis Petridis, 195315
Frailty index is a strong predictor of both in-hospital outcomes and after-discharge mortality in cirrhotic patients.
AASLD LiverLearning®, Gaia Caccamo, 195316
Fractional Excretion Of Urea Is A Simple Tool To Aid The Differential Diagnosis of Acute Kidney Injury in Advanced Liver Disease
AASLD LiverLearning®, Kavish Patidar, 195317
Terlipressin Use, Transplant Rate, and Post-Transplant Outcomes in Patients With Type 1 Hepatorenal Syndrome (HRS)
AASLD LiverLearning®, Samuel Sigal, 195318
Dose Dependent Impact of Proton Pump Inhibitors on the Clinical Course of Spontaneous Bacterial Peritonitis
AASLD LiverLearning®, Tammo Tergast, 195319
Trajectory of Serum Creatinine in Liver Transplant Candidates Identifies Patients at High Risk of Mortality
AASLD LiverLearning®, Allison Kwong, 195320